Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Radiation Oncology
ALK+
Questions discussed in this category
Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?
2 Answers available
How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?
Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?
5 Answers available
3453
6025
Papers discussed in this category
The New England journal of medicine, 2018-12-13
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Related Topics in Radiation Oncology
Lung Cancer
Workload
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers